Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
ADRB2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METAPROTERENOL | ↑ activates | Mechanistic | DGIdb | |
| PROPRANOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| OLODATEROL | ↑ activates | Mechanistic | DGIdb | |
| TIMOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1465049 | ? unclear | Mechanistic | DGIdb | |
| NOREPINEPHRINE | ↑ activates | Mechanistic | DGIdb | |
| EPHEDRINE SULFATE | ↑ activates | Mechanistic | DGIdb | |
| LEVALBUTEROL | ? unclear | Mechanistic | DGIdb | |
| 3-O-METHYLQUERCETIN | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| CLENBUTEROL | ↑ activates | Mechanistic | DGIdb | |
| ARFORMOTEROL | ? unclear | Mechanistic | DGIdb | |
| CELIPROLOL | ↑ activates | Mechanistic | DGIdb | |
| ISOPROTERENOL | ↑ activates | Mechanistic | 0.1585 nM (EC50) | DGIdb |
| MEPHENTERMINE SULFATE | ↑ activates | Mechanistic | DGIdb | |
| CARVEDILOL | ↓ inhibits | Mechanistic | DGIdb | |
| PROCATEROL | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL590927 | ? unclear | Mechanistic | DGIdb | |
| TERTATOLOL | ? unclear | Mechanistic | DGIdb | |
| FENOTEROL | ↑ activates | Mechanistic | DGIdb | |
| MEPINDOLOL | ? unclear | Mechanistic | DGIdb | |
| PROPAFENONE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL531322 | ? unclear | Mechanistic | DGIdb | |
| CARMOTEROL | ↑ activates | Mechanistic | DGIdb | |
| PINDOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| SALMETEROL | ↑ activates | Mechanistic | DGIdb | |
| CGP12177 | ↓ inhibits | Mechanistic | DGIdb | |
| CLENBUTEROL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| NADOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| DESIPRAMINE | ? unclear | Mechanistic | DGIdb | |
| CIMATEROL | ↑ activates | Mechanistic | DGIdb | |
| FENOTEROL HBR | ? unclear | Mechanistic | DGIdb | |
| RITODRINE | ? unclear | Mechanistic | DGIdb | |
| PF-00610355 | ? unclear | Mechanistic | DGIdb | |
| SOTALOL | ↓ inhibits | Mechanistic | DGIdb | |
| TERBUTALINE | ↑ activates | Mechanistic | DGIdb | |
| LAS190792 | ↑ activates | Mechanistic | DGIdb | |
| NORADRENALINE | ↑ activates | Mechanistic | DGIdb | |
| LEVOBUNOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PENBUTOLOL SULFATE | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 368 agents ranked by evidence tier.
ATP5F1A
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHEMBL5286255 | ↓ inhibits | Mechanistic | 0.7 nM (Ki) | ChEMBL |
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA EXTRACT | ? unclear | Mechanistic | DGIdb | |
| NELFINAVIR | ? unclear | Mechanistic | DGIdb | |
| SELECTIVE ESTROGEN RECEPTOR MODULATOR | ? unclear | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| SITAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| PACIBEKITUG | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| SAFINGOL | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| RITUXIMAB | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| C326 | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| OSIMERTINIB | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| ALOGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| TENELIGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| TOCILIZUMAB | ? unclear | Mechanistic | DGIdb | |
| LINAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| VILDAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| PAREGORIC | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 181 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DICLOFENAC SODIUM | ? unclear | Mechanistic | DGIdb | |
| RDP58 | ? unclear | Mechanistic | DGIdb | |
| METHYLENE BLUE | ? unclear | Mechanistic | DGIdb | |
| ORTATAXEL | ? unclear | Mechanistic | DGIdb | |
| CERTOLIZUMAB PEGOL | ↓ inhibits | Mechanistic | DGIdb | |
| OZORALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| HUANG LIAN | ? unclear | Mechanistic | DGIdb | |
| GOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CYCLOSPORINE | ? unclear | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| HALOFUGINONE | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ISIS 104838 | ? unclear | Mechanistic | DGIdb | |
| GEMCITABINE | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| DIDANOSINE | ? unclear | Mechanistic | DGIdb | |
| 5,7-DIHYDROXY-4-METHYLCOUMARIN | ? unclear | Mechanistic | DGIdb | |
| SOBLIDOTIN | ? unclear | Mechanistic | DGIdb | |
| STAVUDINE | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| MEROPENEM ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| AMPHOTERICIN B LIPOSOMAL | ? unclear | Mechanistic | DGIdb | |
| MIDAZOLAM HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| RIFAMPIN | ? unclear | Mechanistic | DGIdb | |
| AVX-470 | ? unclear | Mechanistic | DGIdb | |
| KETOROLAC TROMETHAMINE | ? unclear | Mechanistic | DGIdb | |
| PRAZOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| BENZO[E]PYRENE | ? unclear | Mechanistic | DGIdb | |
| ETHAMBUTOL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| REMTOLUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SPIRONOLACTONE | ? unclear | Mechanistic | DGIdb | |
| OMEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| MITOMYCIN C ANALOG KW-2149 | ? unclear | Mechanistic | DGIdb | |
| NAFAMOSTAT | ? unclear | Mechanistic | DGIdb | |
| ABBV-3373 | ~ modulates | Mechanistic | DGIdb | |
| BACILLUS CALMETTE-GUERIN ANTIGEN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 287 agents ranked by evidence tier.
TRPV1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| RHTX | ↑ activates | Mechanistic | DGIdb | |
| ABT-102 | ↓ inhibits | Mechanistic | DGIdb | |
| ASIVATREP | ↓ inhibits | Mechanistic | DGIdb | |
| BCTC | ↓ inhibits | Mechanistic | DGIdb | |
| MAVATREP | ↓ inhibits | Mechanistic | DGIdb | |
| POLYGODIAL | ? unclear | Mechanistic | DGIdb | |
| ALLICIN | ↓ inhibits | Mechanistic | DGIdb | |
| JTS-653 | ↓ inhibits | Mechanistic | DGIdb | |
| SB452533 | ↓ inhibits | Mechanistic | DGIdb | |
| MR-1817 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-6211 | ↓ inhibits | Mechanistic | DGIdb | |
| ACETAMINOPHEN | ↑ activates | Mechanistic | DGIdb | |
| DWP05195 | ↓ inhibits | Mechanistic | DGIdb | |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| CAPSAICIN | ↑ activates | Mechanistic | 19.95 nM (EC50) | DGIdb |
| AMG517 | ↓ inhibits | Mechanistic | DGIdb | |
| 5S-HETE | ↑ activates | Mechanistic | DGIdb | |
| BENZYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| MASOPROCOL | ? unclear | Mechanistic | DGIdb | |
| [3H]RESINIFERATOXIN | ↑ activates | Mechanistic | DGIdb | |
| [3H]A778317 | ↓ inhibits | Mechanistic | DGIdb | |
| CAPSAZEPINE | ↓ inhibits | Mechanistic | 120.0 nM (Ki) | DGIdb |
| NABIXIMOLS | ? unclear | Mechanistic | DGIdb | |
| H+ | ↑ activates | Mechanistic | DGIdb | |
| RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN | ? unclear | Mechanistic | DGIdb | |
| NADA | ↓ inhibits | Mechanistic | DGIdb | |
| ZUCAPSAICIN | ↑ activates | Mechanistic | DGIdb | |
| SB366791 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-15300 | ? unclear | Mechanistic | DGIdb | |
| MRS-1477 | ~ modulates | Mechanistic | DGIdb | |
| ANANDAMIDE | ↑ activates | Mechanistic | DGIdb | |
| JNJ17203212 | ↓ inhibits | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| AZD1386 | ↓ inhibits | Mechanistic | DGIdb | |
| CAMPHOR OIL | ↑ activates | Mechanistic | DGIdb | |
| ISOPROPYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| VOACANGINE | ? unclear | Mechanistic | DGIdb | |
| FERRUGINENE B | ? unclear | Mechanistic | DGIdb | |
| PHENYLACETYLRINVANIL | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 187 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are: Does the Lingzhi supplement reduce fatigue symptoms? Is it sa...
This is a 16-week controlled treatment trial of an over-the -counter supplement, hydrogen water, for individuals with ME/CFS patients. An active treatment condition will be compared to a placebo-control condition. The study will also seek confirmation of heart rate variability (HRV) as a biomarker, ...
The goal of this clinical trial is to evaluate the therapeutic value of an approved drug (Vericiguat) in patients with post-COVID-19 syndrome, who suffer from profound tiredness or fatigue, regardless of bed rest.The main questions it aims to answer are: • Does Vericiguat relieve fatigue and/or othe...
The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to pr...
The efficacy and safety of rituximab on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituxima...
This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME/CFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are: * how effectiv...
The main aim of the study is to examine the effect of oral CoQ10 plus NADH (Reconnect®) supplementation twice daily for 8-weeks on the changes in fatigue perception, sleep disturbances, autonomic dysfunction and HRQoL assessed by patient-reported outcome measures in CFS/ME.
In recent years, it has been suggested that nutritional deficiencies may be of causal relevance in individuals with ME/CFS. These include deficiencies of vitamins and trace elements. It is likely that the observed nutritional deficiencies contribute to the core symptoms of the disease. Coenzyme Q10 ...
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a neurological disease. Currently there is no effective treatment for ME/CFS due to unclear etiology of the disease. The aim of this randomized double-blind placebo-control clinical trial is to study the efficacy of the probiotic food su...
The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (M...
Agents Found By Disease-Level Search
Searched directly from “ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 6-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
38 agents shown (approved or with trial evidence) — 37 not found by the gene-target search above.
CBTNOT in gene-target list
NAC 900mg/dayNOT in gene-target list
NAC 3600mg/dayNOT in gene-target list
Hyperbaric oxygen therapyNOT in gene-target list
LingZhi capsuleNOT in gene-target list
CoQ10 plus SeleniumNOT in gene-target list
IA with TheraSorb ® column (Miltenyi)NOT in gene-target list
Floradapt Intensive GINOT in gene-target list
ImmunoadsorptionNOT in gene-target list
Rituximab
CyclophosphamideNOT in gene-target list
Hydrogen water which is prepared from an OTC supplement.NOT in gene-target list
AmpligenNOT in gene-target list
LumbrokinaseNOT in gene-target list
Vericiguat Oral TabletNOT in gene-target list
ASARMNOT in gene-target list
Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks.NOT in gene-target list
Transfer PackageNOT in gene-target list
Follow Up Phone CallsNOT in gene-target list
Rituximab(Genetical Recombination)NOT in gene-target list
Prednisolone 20 mg/ 5 mgNOT in gene-target list
Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)NOT in gene-target list
melatonin plus zincNOT in gene-target list
Coenzyme Q10 plus NADHNOT in gene-target list
phosphoserine plus vitamin CNOT in gene-target list
Acceptance and Commitment Therapy (ACT)NOT in gene-target list
Control groupNOT in gene-target list
Bupivacaine InjectionNOT in gene-target list
Hyperbaric oxygen therapy (HBOT)NOT in gene-target list
A 3-day courseNOT in gene-target list
Waiting listNOT in gene-target list
Intervention GroupNOT in gene-target list
IA with TheraSorb ® columnNOT in gene-target list
GutMagnific™ H.NOT in gene-target list
GutMagnific™ L.NOT in gene-target list
PyridostigmineNOT in gene-target list
Low-Dose NaltrexoneNOT in gene-target list
ProbioticsNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.